drugset / Trial / NCT01393990
A Study of LY2228820 in Participants With Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to determine a safe dose of LY2228820 that may be given to participants with advanced cancer. Part A of this study will consist of dose escalation, and Part B will consist of dose confirmation.
Timeline
- Start
- 2008-09-04
- Primary completion
- 2013-02
- Completion
- 2013-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ralimetinib | Small molecule | 10 mg | Oral |
| Subject | Ralimetinib | Small molecule | 20 mg | Oral |
| Subject | Ralimetinib | Small molecule | 40 mg | Oral |
| Subject | Ralimetinib | Small molecule | 65 mg | Oral |
| Subject | Ralimetinib | Small molecule | 90 mg | Oral |
| Subject | Ralimetinib | Small molecule | 120 mg | Oral |
| Subject | Ralimetinib | Small molecule | 160 mg | Oral |
| Subject | Ralimetinib | Small molecule | 200 mg | Oral |
| Subject | Ralimetinib | Small molecule | 300 mg | Oral |
| Subject | Ralimetinib | Small molecule | 420 mg | Oral |
| Subject | Ralimetinib | Small molecule | 560 mg | Oral |
| Background | Midazolam | Small molecule | — | Oral |
| Background | Tamoxifen | Small molecule | — | — |